NO20001437L - Kombinasjonsterapi for Õ utrydde detekterbart HCV-RNA hos pasienter med kronisk hepatitt C-infeksjon - Google Patents

Kombinasjonsterapi for Õ utrydde detekterbart HCV-RNA hos pasienter med kronisk hepatitt C-infeksjon

Info

Publication number
NO20001437L
NO20001437L NO20001437A NO20001437A NO20001437L NO 20001437 L NO20001437 L NO 20001437L NO 20001437 A NO20001437 A NO 20001437A NO 20001437 A NO20001437 A NO 20001437A NO 20001437 L NO20001437 L NO 20001437L
Authority
NO
Norway
Prior art keywords
infection
patients
combination therapy
chronic hepatitis
hcv rna
Prior art date
Application number
NO20001437A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001437D0 (no
Inventor
Janice K Albrecht
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27130070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20001437(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/938,033 external-priority patent/US6172046B1/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20001437L publication Critical patent/NO20001437L/no
Publication of NO20001437D0 publication Critical patent/NO20001437D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20001437A 1997-09-21 2000-03-20 Kombinasjonsterapi for å utrydde detekterbart HCV-RNA hos pasienter med kronisk hepatitt C-infeksjon NO20001437D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/938,033 US6172046B1 (en) 1997-09-21 1997-09-21 Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US93512397A 1997-09-22 1997-09-22
PCT/US1998/018488 WO1999015194A1 (en) 1997-09-21 1998-09-16 Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection

Publications (2)

Publication Number Publication Date
NO20001437L true NO20001437L (no) 2000-03-20
NO20001437D0 NO20001437D0 (no) 2000-03-20

Family

ID=27130070

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001437A NO20001437D0 (no) 1997-09-21 2000-03-20 Kombinasjonsterapi for å utrydde detekterbart HCV-RNA hos pasienter med kronisk hepatitt C-infeksjon

Country Status (24)

Country Link
EP (3) EP1317929A3 (zh)
JP (1) JPH11152231A (zh)
KR (1) KR20010024188A (zh)
CN (1) CN1250283C (zh)
AR (1) AR013497A1 (zh)
AT (2) ATE230999T1 (zh)
AU (1) AU749924B2 (zh)
BR (1) BR9812484A (zh)
CA (1) CA2245938C (zh)
CO (1) CO4970691A1 (zh)
DE (2) DE69810822T2 (zh)
DK (2) DK1136075T3 (zh)
ES (2) ES2186660T3 (zh)
HK (2) HK1016505A1 (zh)
HU (1) HUP0100092A3 (zh)
IL (1) IL134428A0 (zh)
MY (1) MY117781A (zh)
NO (1) NO20001437D0 (zh)
NZ (1) NZ502740A (zh)
PE (1) PE119199A1 (zh)
PT (1) PT903148E (zh)
SK (1) SK3922000A3 (zh)
TW (1) TW568787B (zh)
WO (1) WO1999015194A1 (zh)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2172288T3 (es) * 1998-05-15 2002-09-16 Schering Corp Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.
AU2157000A (en) * 1998-12-18 2000-07-12 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
WO2000037097A1 (en) * 1998-12-18 2000-06-29 Schering Corporation Ribavirin-interferon alfa induction hcv combination therapy
DE19919585A1 (de) 1999-04-29 2000-12-07 Cmi Ag Verwendung von Phyllanthus zur Behandlung von oxidativem Streß und anderen Symptomen
CA2405563A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA200601591A1 (ru) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
DK1330468T3 (da) 2000-09-18 2007-11-05 Serono Lab Svovlanaloger af 21 hydroxy-6,19-oxido-progesteron (21OH 6OP) til behandling af overskud af glucocorticoider
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
TW200500373A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7456155B2 (en) 2002-06-28 2008-11-25 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
JP2004155777A (ja) * 2002-10-16 2004-06-03 Asahi Kasei Pharma Kk Ｃ型慢性肝炎治療剤
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
SI1633766T1 (sl) 2003-05-30 2019-06-28 Gilead Pharmasset Llc Modificirani analogi fluoriranih nukleozidov
CN1835765A (zh) * 2003-08-13 2006-09-20 霍华德·J·史密斯及同仁控股有限公司 治疗病毒感染的方法
ES2245248B1 (es) * 2004-06-09 2007-02-16 Universidad De Salamanca Uso de la artemisinina y sus derivados en la fabricacion de medicamentos utiles como agentes antiviricos.
NZ554442A (en) 2004-09-14 2011-05-27 Pharmasset Inc Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
MX2010000965A (es) 2007-07-25 2010-03-09 Biolex Therapeutics Inc Productos de farmaco de interferon de liberacion controlada y tratamiento de la infeccion del virus de hepatitis c usando los mismos.
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
EP2671888A1 (en) 2008-12-23 2013-12-11 Gilead Pharmasset LLC 3',5'-cyclic nucleoside phosphate analogues
EA201100851A1 (ru) 2008-12-23 2012-04-30 Фармассет, Инк. Аналоги нуклеозидов
MX2011006891A (es) 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
ES2537785T3 (es) 2009-05-08 2015-06-12 Sciclone Pharmaceuticals, Inc. Péptidos de alfa timosina como potenciadores de vacunas
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
EP2552931B1 (en) 2010-03-31 2014-07-23 Gilead Pharmasset LLC Stereoselective synthesis of phosphorus containing actives
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
BR112014006324B8 (pt) 2011-09-16 2019-02-12 Gilead Pharmassett Llc composição e seu uso para o tratamento de hcv
CH707029B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
WO2015136455A1 (en) * 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection

Also Published As

Publication number Publication date
EP0903148B1 (en) 2001-10-10
EP1136075A1 (en) 2001-09-26
CN1250283C (zh) 2006-04-12
DK1136075T3 (da) 2003-04-28
HUP0100092A2 (hu) 2001-05-28
DE69810822T2 (de) 2003-11-20
HK1041440B (zh) 2003-09-05
MY117781A (en) 2004-08-30
CA2245938A1 (en) 1999-03-21
WO1999015194A1 (en) 1999-04-01
TW568787B (en) 2004-01-01
EP1317929A2 (en) 2003-06-11
DE69810822D1 (de) 2003-02-20
EP1136075B1 (en) 2003-01-15
ES2186660T3 (es) 2003-05-16
SK3922000A3 (en) 2000-10-09
BR9812484A (pt) 2000-09-19
ES2162393T3 (es) 2001-12-16
DK0903148T3 (da) 2001-12-17
EP0903148A2 (en) 1999-03-24
CA2245938C (en) 2003-07-15
AU749924B2 (en) 2002-07-04
EP1317929A3 (en) 2003-07-02
HUP0100092A3 (en) 2002-03-28
CO4970691A1 (es) 2000-11-07
PE119199A1 (es) 1999-12-01
CN1271292A (zh) 2000-10-25
HK1041440A1 (en) 2002-07-12
IL134428A0 (en) 2001-04-30
AR013497A1 (es) 2000-12-27
DE69801970D1 (de) 2001-11-15
NO20001437D0 (no) 2000-03-20
NZ502740A (en) 2002-10-25
AU9473798A (en) 1999-04-12
EP0903148A3 (en) 1999-04-28
ATE206618T1 (de) 2001-10-15
HK1016505A1 (en) 1999-11-05
KR20010024188A (ko) 2001-03-26
DE69801970T2 (de) 2002-06-13
PT903148E (pt) 2002-02-28
ATE230999T1 (de) 2003-02-15
JPH11152231A (ja) 1999-06-08

Similar Documents

Publication Publication Date Title
NO20001437L (no) Kombinasjonsterapi for Õ utrydde detekterbart HCV-RNA hos pasienter med kronisk hepatitt C-infeksjon
NO20005755L (no) Kombinasjonsterapi omfattende ribavirin og interferon-<alfa> hos antivirusbehandlingsnaive pasienter med kronisk hepatitt C- infeksjon
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
BR0114636A (pt) Terapia combinada para hcv de interferon-alfa peguilado/ribavirina
HU228218B1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
AU2001255495A1 (en) Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
AR023541A1 (es) Terapia de combinacion para vhc
ATE284408T1 (de) Ribavirin-interferon-alpha-kombinationstherapie zur vernichtung nachweisbarer hcv-rna in chronisch hepatitis c infizierten patienten
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
ID28053A (id) Perlakuan asam nukleat enzimatis pada penyakit-penyakit atau kondisi-kondisi yang berkaitan dengan infeksi virus hepatitis c
DK1311279T3 (da) Behandling af hepatitis C med thymosin, interferon og ribavirin
ID24720A (id) Senyawa amidino tersubstitusi dalam perawatan penyakit gangguan paru-paru kronis
DE29612370U1 (de) Hypotraumatische Kanüle (Injektionskanüle mit reduzierendem Traumatisierungseffekt)
ECSP993178A (es) Terapia combinatoria con ribarvirina -interferon alfa para erradicar el hcv - rna detectable en aquellos pacientes que presentan infeccion por hepatitis c cronica

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application